Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days (DrugBank: Betamethasone, Acetate, Phosphate)
6 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 1 |
28 | Systemic amyloidosis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
90 | Retinitis pigmentosa | 0 |
96 | Crohn disease | 0 |
235 | Hypoparathyroidism | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03707795 (ClinicalTrials.gov) | August 21, 2017 | 14/9/2017 | Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study | Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study | Familial Amyotrophic Lateral Sclerosis | Drug: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days | Edward Kasaraskis | NULL | Completed | 20 Years | 80 Years | All | 6 | Early Phase 1 | United States |